NAV

Dexpropranolol

Identification

Generic Name
Dexpropranolol
DrugBank Accession Number
DB03322
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 259.3434
Monoisotopic: 259.157228921
Chemical Formula
C16H21NO2
Synonyms
  • (+)-1-Isopropylamino-3-(1-naphthyloxy)-2-propanol
  • (+)-Propranolol
  • (R)-(+)-propranolol
  • 2R-Propranolol
  • D-Propranolol
  • Dexpropranolol
  • R (+)-Propanolol
  • R-(+)-Propranolol

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbaloparatideAbaloparatide may increase the hypotensive activities of Dexpropranolol.
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Dexpropranolol.
AcebutololAcebutolol may increase the arrhythmogenic activities of Dexpropranolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Dexpropranolol.
AcemetacinAcemetacin may decrease the antihypertensive activities of Dexpropranolol.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Dexpropranolol.
AcetophenazineThe serum concentration of Dexpropranolol can be increased when it is combined with Acetophenazine.
AcetylcholineThe risk or severity of adverse effects can be increased when Dexpropranolol is combined with Acetylcholine.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Dexpropranolol.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Dexpropranolol.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
1,2-aminoalcohol / Alcohol / Alkyl aryl ether / Amine / Aromatic homopolycyclic compound / Ether / Hydrocarbon derivative / Naphthalene / Organic nitrogen compound / Organic oxygen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
propranolol (CHEBI:8736)
Affected organisms
Not Available

Chemical Identifiers

UNII
PG6KY07UD7
CAS number
5051-22-9
InChI Key
AQHHHDLHHXJYJD-CQSZACIVSA-N
InChI
InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3/t14-/m1/s1
IUPAC Name
(2R)-1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol
SMILES
CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=CC=C2

References

General References
Not Available
KEGG Compound
C11193
PubChem Compound
21138
PubChem Substance
46504537
ChemSpider
19877
BindingDB
60973
ChEBI
8736
ChEMBL
CHEMBL275742
ZINC
ZINC000000020240
PDBe Ligand
SNP
Wikipedia
Propranolol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0794 mg/mLALOGPS
logP3.03ALOGPS
logP2.58Chemaxon
logS-3.5ALOGPS
pKa (Strongest Acidic)14.09Chemaxon
pKa (Strongest Basic)9.67Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area41.49 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity76.83 m3·mol-1Chemaxon
Polarizability30.05 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier-0.9031
Caco-2 permeable+0.6942
P-glycoprotein substrateSubstrate0.7079
P-glycoprotein inhibitor IInhibitor0.5588
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6463
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.924
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8487
Ames testNon AMES toxic0.9392
CarcinogenicityNon-carcinogens0.9097
BiodegradationNot ready biodegradable0.9871
Rat acute toxicity2.5625 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9185
hERG inhibition (predictor II)Inhibitor0.7092
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 13, 2005 13:24 / Updated at February 21, 2021 18:51